US2012016465A1PendingUtilityA1

Biodegradable Extravascular Stent

44
Assignee: KOOPMAN JACOB LAURENSPriority: Feb 6, 2009Filed: Feb 5, 2010Published: Jan 19, 2012
Est. expiryFeb 6, 2029(~2.5 yrs left)· nominal 20-yr term from priority
Inventors:Jacob Koopman
A61L 2300/418A61L 27/507A61L 31/14A61L 31/16A61L 31/046A61L 27/34A61L 31/041A61L 31/042A61L 27/225
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable.

Claims

exact text as granted — not AI-modified
1 . An extravascular fibrin polymer stent obtainable by coating a vein with a dry powder formulation comprising fibrinogen and a fibrinogen activator. 
     
     
         2 . An extravascular fibrin polymer stent according to  claim 1 , wherein the fibrinogen or the fibrinogen activator is in a recombinant or a variant form. 
     
     
         3 . An extravascular fibrin polymer stent according to  claim 1 , wherein the dry powder formulation further comprises a carbohydrate, preferably trehalose, sucrose or lactose. 
     
     
         4 . An extravascular fibrin polymer sent according to  claim 1 , wherein the dry powder formulation is obtained by spray-drying. 
     
     
         5 . An extravascular fibrin polymer stent according to  claim 1 , wherein the dry powder formulation comprises the fibrinogen and fibrinogen activator in separate particles or microparticles. 
     
     
         6 . An extravascular fibrin polymer stent according to  claim 1 , wherein the vein is a venous graft. 
     
     
         7 . An extravascular fibrin polymer stent according to  claim 1 , wherein the fibrinogen activator is thrombin or reptilase. 
     
     
         8 . An extravascular fibrin polymer stent according to  claim 7 , wherein the dry powder formulation comprises 10 mg-1 g of fibrinogen and 0.1-10 000 IU of thrombin per dose of dry powder formulation. 
     
     
         9 . An extravascular fibrin polymer stent according to  claim 7 , wherein the dry powder formulation comprises 1-30% w/w of fibrinogen and 0.1-1000 IU of thrombin per gram of dry powder formulation. 
     
     
         10 . (canceled) 
     
     
         11 . A vein surrounded by an extravascular stent according to  claim 1 . 
     
     
         12 . A method of producing an extravascular fibrin polymer stent, which method comprises applying to a segment or to the whole of a vein a dry powder formulation of fibrinogen and a fibrinogen activator. 
     
     
         13 . A method according to  claim 12 , wherein the dry powder formulation of fibrinogen and fibrinogen activator is applied to the vein before introducing the vein in a human or animal body. 
     
     
         14 . A method according to  claim 12 , wherein the fibrinogen or the fibrinogen activator is in a recombinant or a variant form. 
     
     
         15 . A method according to  claim 12 , wherein the dry powder formulation further comprises a carbohydrate, preferably trehalose, sucrose or lactose. 
     
     
         16 . A method according to  claim 12 , wherein the dry powder formulation is obtained by spray-drying. 
     
     
         17 . A method according to  claim 12 , wherein the fibrinogen and the fibrinogen activator are presented in separate particles or microparticles in the dry powder formulation. 
     
     
         18 . A method according to  claim 12 , wherein the vein is a venous graft. 
     
     
         19 . A method according to  claim 12 , wherein the fibrinogen activator is thrombin or reptilase. 
     
     
         20 . A method according to  claim 19 , wherein the dry powder formulation comprises 10 mg-1 g of fibrinogen and 0.1-10000 IU of thrombin per dose of dry powder formulation. 
     
     
         21 . A method according to  claim 19 , wherein the dry powder formulation comprises 1-30% w/w of fibrinogen and 0.1-1000 IU of thrombin per gram of dry powder formulation. 
     
     
         22 . (canceled) 
     
     
         23 . A method of preventing or treating vein graft disease, comprising the step of implanting an extravascular fibrin polymer stent prepared using a dry powder formulation of fibrinogen and a fibrinogen activator. 
     
     
         24 . The method according to  claim 23  for preventing or treating overextension of a vein using an extravascular fibrin polymer stent. 
     
     
         25 . The method according to  claim 23 , wherein the fibrinogen and the fibrinogen activator are presented in separate particles or microparticles in the dry powder formulation. 
     
     
         26 . The method according to  claim 23 , wherein the fibrinogen activator is thrombin or reptilase.

Join the waitlist — get patent alerts

Track US2012016465A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.